Tao Chen
Research Subjects
Research Interests
Tao Chen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Haonan Chen
The First Clinical Medical School, Guangdong Pharmaceutical University, 510006 Guangzhou, Guangdong, China
1 shared publication - Houde He
Department of Epidemiology , School of Public Health , Southern Medical University , Guangzhou 510515 , China , fimmu.com
1 shared publication - Lina Guo
Clinical Nutrition Department, Guangdong Provincial Hospital of Chinese Medicine, 510030 Guangzhou, Guangdong, China
1 shared publication - Wang Zhao
Neurology Department, The People's Hospital of Chizhou, 247100 Chizhou, Anhui, China
1 shared publication - Yan Liu
Guangdong Medical University
1 shared publication - Yongcheng Jiang
Neurology Department, The People's Hospital of Chizhou, 247100 Chizhou, Anhui, China
1 shared publication
Latest Publications
- Open Access
- 26 June 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (6) , 39587
Lactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA
Background: Insomnia, the most prevalent sleep disorder, is clinically defined as difficulty initiating or maintaining sleep. Although many medications are effective for insomnia treatment, they carry risks of drug dependence and abuse. The microbiota-gut-brain axis (MGBA) facilitates bidirectional signaling between the gastrointestinal tract and the central nervous system via gut microbes. Probiotics that provide mental and behavioral benefits through MGBA (psychobiotics) offer broad therapeutic potential. Methods: A non-toxic, drug-resistant strain of Lactobacillus reuteri E9 was isolated and characterized. Its effects were evaluated in a pentylenetetrazol (PTZ)-induced zebrafish model of sleep disorder. Neurotransmitter levels (glycine, serine, taurine, γ-aminobutyric acid (GABA)) and gene expression of GABA/melatonin receptors were analyzed. Results: E9 significantly upregulated inhibitory neurotransmitters, including GABA, taurine, glycine, and serine (p < 0.05). In PTZ-induced zebrafish, E9 exerted sedative effects by reducing seizures and hyperactivity. Concurrently, E9 upregulated the expression of GABA receptor genes and melatonin receptor (Mtnr1aa) genes in zebrafish neural tissue. Conclusions: Lactobacillus reuteri E9 demonstrates potential as a psychobiotic for sleep disorder management by modulating key inhibitory neurotransmitters and sleep-related receptor expression via the MGBA pathway, offering a non-pharmacological alternative to conventional treatments.
- 26 June 2025
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 30 (6) , 39587
Open AccessLactobacillus reuteri E9 Regulates Sleep Disorders Through Its Metabolite GABA
Background: Insomnia, the most prevalent sleep disorder, is clinically defined as difficulty initiating or maintaining sleep. Although many medications are effective for insomnia treatment, they carry risks of drug dependence and abuse. The microbiota-gut-brain axis (MGBA) facilitates bidirectional signaling between the gastrointestinal tract and the central nervous system via gut microbes. Probiotics that provide mental and behavioral benefits through MGBA (psychobiotics) offer broad therapeutic potential. Methods: A non-toxic, drug-resistant strain of Lactobacillus reuteri E9 was isolated and characterized. Its effects were evaluated in a pentylenetetrazol (PTZ)-induced zebrafish model of sleep disorder. Neurotransmitter levels (glycine, serine, taurine, γ-aminobutyric acid (GABA)) and gene expression of GABA/melatonin receptors were analyzed. Results: E9 significantly upregulated inhibitory neurotransmitters, including GABA, taurine, glycine, and serine (p < 0.05). In PTZ-induced zebrafish, E9 exerted sedative effects by reducing seizures and hyperactivity. Concurrently, E9 upregulated the expression of GABA receptor genes and melatonin receptor (Mtnr1aa) genes in zebrafish neural tissue. Conclusions: Lactobacillus reuteri E9 demonstrates potential as a psychobiotic for sleep disorder management by modulating key inhibitory neurotransmitters and sleep-related receptor expression via the MGBA pathway, offering a non-pharmacological alternative to conventional treatments.